These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 36502529)

  • 1. Discovery of octahydropyrrolo [3,2-b] pyridin derivative as a highly selective Type I inhibitor of FGFR3 over VEGFR2 by high-throughput virtual screening.
    Wang X; Ye CH; Li EM; Xu LY; Lin WQ; Chen GH
    J Cell Biochem; 2023 Feb; 124(2):221-238. PubMed ID: 36502529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular dynamics guided insight, binding free energy calculations and pharmacophore-based virtual screening for the identification of potential VEGFR2 inhibitors.
    Rathi E; Kumar A; Kini SG
    J Recept Signal Transduct Res; 2019; 39(5-6):415-433. PubMed ID: 31755336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-based drug design of 1,3,5-triazine and pyrimidine derivatives as novel FGFR3 inhibitors with high selectivity over VEGFR2.
    Kuriwaki I; Kameda M; Hisamichi H; Kikuchi S; Iikubo K; Kawamoto Y; Moritomo H; Kondoh Y; Amano Y; Tateishi Y; Echizen Y; Iwai Y; Noda A; Tomiyama H; Suzuki T; Hirano M
    Bioorg Med Chem; 2020 May; 28(10):115453. PubMed ID: 32278710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of novel VEGFR2-TK inhibitors by phthalimide pharmacophore based virtual screening, molecular docking, MD simulation and DFT.
    Matore BW; Roy PP; Singh J
    J Biomol Struct Dyn; 2023; 41(22):13056-13077. PubMed ID: 36775656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ligand-Based Pharmacophore Modeling, Molecular Docking, and Molecular Dynamic Studies of Dual Tyrosine Kinase Inhibitor of EGFR and VEGFR2.
    Sangande F; Julianti E; Tjahjono DH
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33096664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Computational Investigation of 1, 3, 4 Oxadiazole Derivatives as Lead Inhibitors of VEGFR 2 in Comparison with EGFR: Density Functional Theory, Molecular Docking and Molecular Dynamics Simulation Studies.
    Bilal MS; Ejaz SA; Zargar S; Akhtar N; Wani TA; Riaz N; Aborode AT; Siddique F; Altwaijry N; Alkahtani HM; Umar HI
    Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36358960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of potentially high drug-like VEGFR2/c-Met dual-target type II kinase inhibitors with symmetric skeletons based on structural screening.
    Xie J; Zhang X; Meng D; Li Y; Deng P
    J Biomol Struct Dyn; 2024; 42(3):1249-1267. PubMed ID: 37042992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacophore and Docking Guided Virtual Screening Study for Discovery of Type I Inhibitors of VEGFR-2 Kinase.
    Bhojwani HR; Joshi UJ
    Curr Comput Aided Drug Des; 2017; 13(3):186-207. PubMed ID: 27981900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of tyrosine kinase inhibitors from Panax bipinnatifidus and Panax pseudoginseng for RTK-HER2 and VEGFR2 receptors, by in silico approach.
    Paul D; Mahanta S; Tag H; Das SK; Das Gupta D; Tanti B; Ananthan R; Das R; Jambhulkar S; Hui PK
    Mol Divers; 2022 Aug; 26(4):1933-1955. PubMed ID: 34554395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of novel PI3Kδ inhibitors by docking, ADMET prediction and molecular dynamics simulations.
    Liu YY; Feng XY; Jia WQ; Jing Z; Xu WR; Cheng XC
    Comput Biol Chem; 2019 Feb; 78():190-204. PubMed ID: 30557817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of potential PKC inhibitors through pharmacophore designing, 3D-QSAR and molecular dynamics simulations targeting Alzheimer's disease.
    Iqbal S; Anantha Krishnan D; Gunasekaran K
    J Biomol Struct Dyn; 2018 Nov; 36(15):4029-4044. PubMed ID: 29182053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Uncovering Molecular Bases Underlying Bone Morphogenetic Protein Receptor Inhibitor Selectivity.
    Alsamarah A; LaCuran AE; Oelschlaeger P; Hao J; Luo Y
    PLoS One; 2015; 10(7):e0132221. PubMed ID: 26133550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular dynamics simulation and free energy calculation studies of kinase inhibitors binding to active and inactive conformations of VEGFR-2.
    Wu X; Wan S; Wang G; Jin H; Li Z; Tian Y; Zhu Z; Zhang J
    J Mol Graph Model; 2015 Mar; 56():103-12. PubMed ID: 25594497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring binding mechanisms of VEGFR2 with three drugs lenvatinib, sorafenib, and sunitinib by molecular dynamics simulation and free energy calculation.
    Wang Y; Peng C; Wang G; Xu Z; Luo Y; Wang J; Zhu W
    Chem Biol Drug Des; 2019 May; 93(5):934-948. PubMed ID: 30689282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A combinatorial in silico and cellular approach to identify a new class of compounds that target VEGFR2 receptor tyrosine kinase activity and angiogenesis.
    Kankanala J; Latham AM; Johnson AP; Homer-Vanniasinkam S; Fishwick CW; Ponnambalam S
    Br J Pharmacol; 2012 May; 166(2):737-48. PubMed ID: 22141913
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Das SK; Deka SJ; Paul D; Gupta DD; Das TJ; Maravi DK; Tag H; Hui PK
    J Biomol Struct Dyn; 2022 Sep; 40(15):6857-6867. PubMed ID: 33625319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular modeling study of the induced-fit effect on kinase inhibition: the case of fibroblast growth factor receptor 3 (FGFR3).
    Li Y; Delamar M; Busca P; Prestat G; Le Corre L; Legeai-Mallet L; Hu R; Zhang R; Barbault F
    J Comput Aided Mol Des; 2015 Jul; 29(7):619-41. PubMed ID: 25808135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of Flavonoids as Putative ROS-1 Kinase Inhibitors Using Pharmacophore Modeling for NSCLC Therapeutics.
    Parate S; Kumar V; Hong JC; Lee KW
    Molecules; 2021 Apr; 26(8):. PubMed ID: 33917039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacophore modeling and virtual screening in search of novel Bruton's tyrosine kinase inhibitors.
    Sharma A; Thelma BK
    J Mol Model; 2019 Jun; 25(7):179. PubMed ID: 31172362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of tyrosine kinase inhibitors by docking into an inactive kinase conformation generated by molecular dynamics.
    Zhao H; Huang D; Caflisch A
    ChemMedChem; 2012 Nov; 7(11):1983-90. PubMed ID: 22976951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.